Lifecarenews’ Post

Iktos appoints new Scientific Advisory Board with

Iktos appoints new Scientific Advisory Board with

📹 In this video interview, Jane Myles, program director, Decentralized Trials & Research Alliance (DTRA), highlights how DTRA is working with sites and sponsors to gauge the feasibility of site-validated technology use.

Important piece: Meta-Research: Blinding reduces institutional prestige bias during initial review of applications for a young investigator award I also have some issues with young investigators awards - I often feel them as awards going (in fact/de facto) to supervisors and group leaders instead of the researcher... Or at least often it is hard to tell whether the researcher below 30 or 35 is really independent and independently brilliant, or is only a well-mentored, diligent, hard-working, clever person who works under a world-renowned researcher... https://lnkd.in/dp_AeHQf

CrystalsFirst is thrilled to announce our joining of the PROXIDRUGS consortium, a groundbreaking initiative developing innovative proximity-inducing drugs to target disease-causing proteins within cells. By joining PROXIDRUGS, CrystalsFirst aligns itself with a visionary project that spans the entire preclinical drug development pipeline. This collaboration promises to accelerate the translation of cutting-edge research into tangible therapeutic solutions, potentially transforming patient outcomes across multiple disease areas. PROXIDRUGS is at the forefront of a revolutionary approach to drug discovery. This consortium brings together leading experts to create better therapies for a wide range of diseases, including cancer, inflammatory disorders, infectious diseases, and neurodegenerative conditions. The core of PROXIDRUGS' strategy lies in proximity-based pharmaceuticals, a novel class of drugs with the potential to degrade approximately 80% of disease-relevant proteins. This approach opens up new possibilities for treating conditions that have long eluded effective therapies. We look forward to contributing our expertise to this consortium and working alongside academic and industry partners to push the boundaries of drug discovery. Together, we aim to unlock new paradigms in personalized medicine and address critical unmet medical needs. https://lnkd.in/gGipGArD

💡Thinking about OoC qualificaton? 🤔 Wondering which elements to consider? 👩🔬Curious about practical considerations by experts in the field?   Have a look at our recently published paper that summarises the outcome of last year workshop "Heads on! Designing a qualification framework for organ-on-chip" https://lnkd.in/eaqSfXhM   Milena Mennecozzi, Stavroula Sampani, Maurice Whelan   #EU #Research #ECVAM #Science4Policy #3Rs #qualification #Innovation #NonAnimalMethods #OoC #organonchip

Indeed I share the Arnoldas Doviltis ‘s comment. #accesstoinnovation should be a top priority in #eu. #defense, #healthcare and #energy must be the main priorities as also stressed in the Draghi’s report on recovering competitiveness and reindustrializing europe Serban & Musneci Associates Camera di Commercio Italiana per la Romania (CCIpR) ARPIM - The Romanian Association of International Medicine Manufacturers

Roberto Musneci, Senior Partner Serban & Musneci Associates, emphasizes the importance of the European Union focusing on four strategic priorities: innovation, defense, health, and energy. In a time marked by economic and geopolitical challenges, these areas form the foundation for a more resilient, competitive, and future-ready Europe. #EuropeanUnion #Innovation #Healthcare #Energy #Defense #FutureForward

CNUCOP’s Class of 2025 student, Mr. Karim Pajazetovic, was selected to present a poster at the recently concluded 2024 ASPET meeting with a $1,000 travel award from ASPET. Karim was also invited for an oral/podium presentation in a limited event on the use of machine learning/AI in drug discovery and pharmacology education. There were 3 panelists in this podium presentation and aside from Karim, the other two are senior directors from AstraZeneca and Allucent. Karim's podium presentation was very well received and he received an on-the-spot offer from an FDA recruiter for an FDA-based post-doctoral training. Here are the first 5 minutes of his podium presentation. https://lnkd.in/grJHzufe FACILITATING DRUG DISCOVERY AND DEVELOPMENT USING AI / MACHINE LEARNING Co-Sponsored by the American College of Clinical Pharmacology Artificial Intelligence (AI) and Machine Learning (ML) are poised to be transformational technologies in multiple aspects of pharmacology, enabling researchers to utilize real-world data to better inform key decisions at multiple stages of the drug discovery and development process. In particular, the application of these technologies to the disciplines of translational and clinical pharmacology could have a tremendous impact on both target identification and drug development. This session will provide a broad set of perspectives on potential applications of AI/ML in pharmacology, covering how it could be used to (1) facilitate reverse translational efforts/target discovery using existing data sets; (2) make dose recommendations and predict drug interactions and adverse reactions; (3) and to optimize the exposure, safety, and efficacy of drugs. By covering practical examples of how AI/ML can be applied, this session will provide a thought-provoking overview of the utility of these technologies in pharmacology. CHAIRS Ross Corriden and Robert Bies SPEAKERS Application of Machine Learning in Translational Medicine Lisa Benincosa - Allucent The Potential/Pitfalls of AI in Clinical Pharmacology Megan Gibbs - AstraZeneca A GPT4-based Patient Simulation to Enhance the Integration of Pharmacology with Clinical Decision Making in a PharmD Program Karim Pajazetovic - California Northstate University

In a study on hypercholesterolemia the effects of monoclonal antibody inhibitors of PCSK9 were investigated. This study dives into the pharmacotherapy of hypercholesterolemia. In hypercholesterolemia lipid levels are elevated due to mutations in LDL receptors (Siemens et al., 2024). With this diagnosis patients are at a greater risk of developing atherosclerotic cardiovascular disease, therefore patients are often started on an aggressive lipid lowering pharmacotherapy (Siemens et al., 2024). The first line treatment is to start on a high intensity statin. However, some patients cannot reach their goal of lowering LDL levels, often times it is due to adverse effects (Siemens et al., 2024). Monoclonal antibody inhibitors against PCSK9 have been found to lower LDL levels when patients do not reach their goal with statin therapy (Siemens et al., 2024). It has been found that LDL levels decrease by 50-60% with PCSK9 inhibitors (Siemens et al., 2024). Patients were used from a lipid clinic, who had been diagnosed with HeFH. The goal of the study was to have patients with a ≥50% reduction in LDL concentration after a 12-month period of PCSK9 therapy. It was found that about 75% of patients in the study were able to have LDL concentration reductions ≥50% (Siemens et al., 2024). Therefore, PCSK9 therapy should be considered an alternative if statin therapy is not producing impactful results. Reference Siemens, R., Pryjma, M., Buchkowsky, S., & Barry, A. R. (2024). Real-world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study. Retrieved from https://lnkd.in/g-YbKm_N